IRIS - Res&Arch Institutional Research Information System - Research & Archive

VERSO, Melina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.246
EU - Europa 920
AS - Asia 297
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 2
Totale 2.469
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.240
IE - Irlanda 236
IT - Italia 201
UA - Ucraina 188
SG - Singapore 155
SE - Svezia 69
FI - Finlandia 54
RU - Federazione Russa 52
DE - Germania 43
TR - Turchia 39
HK - Hong Kong 34
CN - Cina 31
VN - Vietnam 27
GB - Regno Unito 23
FR - Francia 14
BE - Belgio 13
AT - Austria 8
NL - Olanda 6
CA - Canada 5
CH - Svizzera 5
UZ - Uzbekistan 5
EU - Europa 3
LB - Libano 3
PL - Polonia 3
BG - Bulgaria 2
BR - Brasile 2
JP - Giappone 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BN - Brunei Darussalam 1
GR - Grecia 1
LT - Lituania 1
MX - Messico 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 2.469
Salva come PNG Salva come JPEG
Città #
Dublin 232
Chandler 215
San Mateo 133
Singapore 119
Jacksonville 111
Perugia 74
Altamura 70
Boardman 67
Ann Arbor 66
Medford 61
Santa Clara 61
Princeton 60
Lawrence 56
Wilmington 45
Andover 41
Izmir 36
Hong Kong 32
Dong Ket 27
Des Moines 26
Ashburn 19
Saint Petersburg 17
Norwalk 15
Brussels 13
San Paolo di Civitate 13
Redmond 11
Helsinki 10
New York 10
Beijing 9
Los Angeles 8
Redwood City 7
Woodbridge 6
Moscow 5
Shanghai 5
Parabiago 4
Rome 4
Kocaeli 3
Vienna 3
Belo Horizonte 2
Den Haag 2
Falls Church 2
Guangzhou 2
Houston 2
London 2
Narni 2
Padova 2
Park Ridge 2
Philadelphia 2
Ponte 2
Salerno 2
Seattle 2
Toronto 2
Bagnara Di Romagna 1
Bandar Seri Begawan 1
Bratislava 1
Charlotte 1
Chicago 1
Dallas 1
Eden Prairie 1
Edinburgh 1
Fairfield 1
Frankfurt am Main 1
Homecourt 1
Lausanne 1
Milan 1
Moggio 1
Munich 1
Napoli 1
Pescara 1
Rostock 1
Sapporo 1
Tokyo 1
Vancouver 1
Totale 1.743
Salva come PNG Salva come JPEG
Nome #
Epidemiology of cerebral vein and sinus thrombosis. 89
Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No. 78
Risk factors for venous thromboembolism in the elderly: results of the master registry. 78
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients 72
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. 70
Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry. 66
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study 60
[Heparin in anesthesia. Pharmacological and clinical aspects in the prophylaxis of venous thromboembolism]. 58
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry 57
Heparin in anesthesia. Pharmacological and clinical aspects in the prophylaxis of venous thromboembolism 56
Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. 56
Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation 56
Dermatan sulphate for heparin-induced thrombocytopenia and central venous catheter-related deep vein thrombosis in a child with acute lymphoblastic leukemia. 55
Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. 53
Do italian vascular centers look for isolated calf deep vein thrombosis? Analysis of isolated calf deep vein thromboses included in the ''Master'' Registry. 51
Chemotherapy-associatedthromboembolic risk in cancer outpatients and effect of nadroparinthromboprophylaxis: results of a retrospective analysis of the PROTECHT study. 51
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism 51
Use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life: comparison with phase III trials 50
Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study 47
Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients 47
Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma 46
Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation 46
Patients aged 90  years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study 46
Seasonal variation in the occurrence of venous thromboembolism: data from the MASTER Registry. 45
New oral anticoagulants and their management in dental practice 45
PL-21 New and old anticoagulants in cancer. 44
Apixaban for the treatment of venous thromboembolism associated with cancer 44
A prospective study on survival in cancer patients with and without venous thromboembolism. 43
Thromboprophylaxis during chemotherapy after advanced cancer. 41
Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry. 41
Vitamin K and non-vitamin K antagonists oral anticoagulants for non-valvular atrial fibrillation in real-life 40
Building effective prophylaxis of deep vein thrombosis in the outpatient setting. Blood Coagul Fibrinolysis. 38
Management of venous thromboembolism in patients with cancer. 38
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 38
Epidemiology of cerebral vein and sinus thrombosis 38
Thrombosis and cancer: clinical relevance of a dangerous liaison. 37
Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. 37
Thromboprophylaxis during chemotherapy in patients with advanced cancer. 36
Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the protecht and topic-2 studies. 35
Real-life use of non-vitamin K antagonist oral anticoagulants in comparison with vitamin K antagonists for non-valvular atrial fibrillation: data from a prospective cohort 35
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. 34
Prophylaxis of upper limb deep vein thrombosis in cancer patients with central vein catheter 34
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). 33
Treatment of venous thromboembolism in patients with cancer: What news from clinical trials? 32
Risk factors of catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. 32
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer 32
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. 31
Therapy insight:venous-catheter-related thrombosis in cancer patients 31
Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism 31
Do antiangiogenics promote clot instability? Data from the TESEO prospective registry and Caravaggio clinical trial. 31
Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life 29
Management of venous thromboembolism in cancer patients: Considerations about the clinical practice guideline update of the American society of clinical oncology 28
Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry 27
The MASTER registry on venous thromboembolism: description of the study cohort. 26
To the editor: The effect of low-molecular-weight heparin in cancer patients: The mirror image of survival? 24
New strategies of VTE prevention in cancer patients. 22
Prophylaxis against venous thromboembolism in patients with cancer [3] 22
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer 22
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence 20
Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding 13
Third national surgical consensus conference of the Italian Association of Breast Surgeons (ANISC) on management after neoadjuvant chemotherapy: The difficulty in reaching a consensus 6
Safety and effectiveness of oral anticoagulants in patients with atrial fibrillation and stage 4 chronic kidney disease: a real-world experience 2
Totale 2.576
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.642
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.642
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020120 0 0 0 0 29 0 30 2 33 17 4 5
2020/2021407 6 30 6 32 135 13 38 11 42 29 34 31
2021/2022505 8 86 8 13 24 4 5 161 6 45 70 75
2022/2023798 67 189 15 44 49 89 0 28 283 1 27 6
2023/2024228 18 25 24 3 3 0 39 9 7 14 50 36
2024/2025230 0 68 1 39 122 0 0 0 0 0 0 0
Totale 2.576